Pediatric and adult patients experienced noninferior and robust immune responses to RIV4, as well as similar safety profiles.

Monoclonal antibodies are fundamental to modern biomedical research, therapeutic development, and diagnostic applications.

Logical Biological launches sister company, Logical Antigen, delivering high-quality antigens and biologicals for in vitro ...

The U.S. Food and Drug Administration has approved a prefilled syringe presentation of Shingrix (zoster vaccine recombinant, ...

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

In recent weeks, Asian markets have shown resilience with the CSI 300 Index and Shanghai Composite Index posting gains, despite ongoing challenges such as China's persistent deflation pressures and a ...

The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and ...

The National Medical Products Administration approved the marketing of a rice-derived recombinant human albumin injection on ...

The global recombinant proteins market size was US$ 1.5 billion in 2021. The global recombinant proteins market is forecasted to grow to US$ 4 billion by 2030 by registering a compound annual growth ...

Protalix BioTherapeutics Inc., a biopharmaceutical company, has appointed Gilad Mamlok as Senior Vice President and Chief ...

Recombinant protein therapy articles from across Nature Portfolio A recombinant protein therapy is produced through recombinant DNA technology, which involves inserting the DNA encoding the ...